AstraZeneca: Rhinitis, Allergic, Seasonal trials

The registry lists 14 Rhinitis, Allergic, Seasonal studies with AstraZeneca as lead sponsor. 0 are open to participants now and 1 have results posted.

Phase 2 2Phase 3 12(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Efficacy and Safety of Ciclesonide Nasal Spray in Participants With Seasonal Allergic Rhinitis (SAR) in RussiaCompletedNCT02155881Phase 3Results posted
• Dose-ranging Study to Assess the Efficacy and Safety of Ciclesonide HFA Nasal Aerosol in Adult and Adolescent Patients 12 Years and Older With Seasonal Allergic Rhinitis (SAR) (BY9010/M1-602)CompletedNCT00807053Phase 2
• To Assess the Safety and Efficacy of Ciclesonide, Applied as a Nasal Spray in the Treatment of Seasonal Allergic Rhinitis (BY9010/M1-401)CompletedNCT00659841Phase 3
• Study Using the Environmental Exposure Chamber (EEC) to Assess the Onset of Action of Ciclesonide, Applied as a Nasal Spray in Treatment of Seasonal Allergic Rhinitis (BY9010/M1-406)CompletedNCT00659594Phase 3
• Study Using the Environmental Exposure Unit (EEU) to Assess the Onset of Action of Ciclesonide, Applied as a Nasal Spray in the Treatment of Seasonal Allergic Rhinitis (BY9010/M1-407)CompletedNCT00659503Phase 3
• To Assess the Safety of Ciclesonide, Applied as a Nasal Spray at Three Dose Levels, in the Treatment of Perennial Allergic Rhinitis in Pediatrics (BY9010/M1-405)CompletedNCT00658918Phase 3
• New Nasal Applicator / New Formulation - User StudyCompletedNCT00641979Phase 2
• Rhinocort Aqua Versus Placebo and Fluticasone PropionateCompletedNCT00641680Phase 3
• A Study of Ciclesonide Nasal Spray in Patients 18 Years and Older With Seasonal Allergic Rhinitis (BY9010/M1-413)CompletedNCT00384475Phase 3
• Safety and Efficacy of Ciclesonide in Pediatric Patients (6 to 11 Years of Age) With Seasonal Allergic Rhinitis (BY9010/M1-417)CompletedNCT00305487Phase 3
• Safety and Tolerability of Ciclesonide Nasal Spray in Patients With Perennial Allergic Rhinitis (2-5 Years Old) (BY9010/M1-416)CompletedNCT00261287Phase 3
• Safety and Effectiveness of Ciclesonide Nasal Spray in Children (6 to 11 Years) With Perennial Allergic Rhinitis (BY9010/M1-403)CompletedNCT00163514Phase 3
• Safety and Effectiveness of Ciclesonide Nasal Spray in Patients With Perennial Allergic Rhinitis During One Year Treatment (BY9010/M1-404)CompletedNCT00163501Phase 3
• Safety of Ciclesonide Nasal Spray Administered With Inhaled Fluticasone Dipropionate/Salmeterol in Adults With Perennial Allergic Rhinitis (BY9010/M1-409)CompletedNCT00163488Phase 3